Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study
Efficacy Cost Analysis: Retrospective Study on the REMOTEV Study's Ancillary Data
1 other identifier
observational
300
1 country
1
Brief Summary
The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first intention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 20, 2019
CompletedStudy Start
First participant enrolled
March 20, 2019
CompletedFirst Posted
Study publicly available on registry
March 25, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2020
CompletedMarch 25, 2019
March 1, 2019
1 year
March 20, 2019
March 21, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cost-effectiveness analysis between 2 therapeutic strategies, Direct Oral Anticoagulants (Rivaroxaban) versus standard anticoagulant (AVK)
Cost-effectiveness analysis between 2 therapeutic strategies: The costs related to each strategy are calculated taking into account the direct and indirect costs.
The period from November 1st, 2013 to July 01, 2015 will be examined
Eligibility Criteria
Patient with a diagnosis of MTEV: pulmonary embolism or deep vein thrombosis diagnosed by the diagnostic reference methods according to the recommendations
You may qualify if:
- Major patient whose age is ≥18 years
- Patient with a diagnosis of MTEV: pulmonary embolism or deep vein thrombosis diagnosed by the diagnostic reference methods according to the recommendations
- Major patient included in the REMOTEV registry
- Patient having accepted that his data recorded in the REMOTEV register be re-used for research and publication purposes
- Refusal to participate in the REMOTEV register
- Patient who refused to have his data reused for research and publication purposes
- Pregnant woman
- Subjects under safeguard of justice Subject under guardianship or curatorship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service Des Maladies Vasculaires - Hta - Nhc
Strasbourg, 67091, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dominique STEPHAN, MD, PhD
University Hospital, Strasbourg, France
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 20, 2019
First Posted
March 25, 2019
Study Start
March 20, 2019
Primary Completion
March 20, 2020
Study Completion
March 20, 2020
Last Updated
March 25, 2019
Record last verified: 2019-03